Prophylaxis and therapy of acquired immunodeficiency syndrome

Details Prophylaxis and therapy of acquired immunodeficiency syndrome Prophylaxis and therapy of acquired immunodeficiency syndrome

1992-02-13

2001-07-24

Housel, James (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

15 to 23 amino acid residues in defined sequence

C530S350000, C530S327000, C424S085100

Reexamination Certificate

active

06265539

ABSTRACT:

FIELD OF THE INVENTION
The present invention concerns a method to prevent or treat acquired immunodeficiency syndrome (AIDS) and involves a new and novel approach for making an immunizing composition or inoculum. The inoculum or composition comprises synthetic peptide multimer that exhibits certain T cell activating immunological characteristics of one or more proteins encoded by the viral causative agent of this disease.
BACKGROUND OF THE INVENTION
AIDS was first recognized in the United States in 1981; the number of cases has been increasing at a dramatic pace since then. Since 1978 more than 2.4 million AIDS infections have been reported in the United States, alone (Rees, Nature, 326:343, 1987). Once significant immunosuppressive symptoms appear in an infected individual, the expected outcome of the infection is death. There is currently no known treatment that can indefinitely delay or prevent the fatal consequences of the disease. Although the disease first manifested itself in homosexual or bisexual males and intravenous drug abusers, it has now spread to others by means such as intimate sexual contact with or receipt of blood products from a carrier of the virus.
The causative agent, associated with AIDS has been identified as a group of closely related retroviruses commonly known as Human T Cell Lymphotrophic Virus-type III (HTLV-III), Lymphadenopathy Viruses (LAV), AIDS-Related Viruses (ARV), or more recently named Human Immunodeficiency Virus (HIV). These viruses will be collectively referred to herein for convenience as HIV.
Like other retroviruses, HIV has RNA as its genetic material. When the virus enters the host cell, a viral enzyme known as reverse transcriptase copies the viral RNA into a double stranded DNA. The viral DNA migrates to the nucleus of the cell where it serves as a template for additional copies of viral RNA which can then be assembled into new viral particles. The viral RNA can also serve as messenger RNA for certain viral proteins [either the viral core proteins (known as p18, p24 and p13)] or the reverse transcriptase, or be “spliced” into specific viral messenger RNAs necessary to produce several other viral proteins including two glycosylated structural proteins known as gp41 and gp120 which are inserted in the outer membrane of the virus (Wain-Hobson et al., Cell 40:9, 1985). A recent study has shown that purified gp120 induces antibody in the goat, horse and rhesus monkey that neutralizes HIV in lab tests (Robey et al., Proc. Natl. Acad. Sci., USA 83:7023, 1986).
Vaccines have been used for many years to prevent infections caused by agents such as viruses. The general approach has been to inject healthy individuals with, for example, a killed or modified virus preparation in order to prime the individual's immune systems to mount an assault on the infecting virus. Recent advances in recombinant DNA technology have allowed safer methods of vaccination that involve use of exposed viral components produced by microbial systems. After sufficient purification, the viral component, for example a protein subunit, is administered as a vaccine in a suitable vehicle and/or an adjuvant. The latter stimulates the host's system in a way that improves the immune response to the viral subunit.
Another potential method of making a vaccine is by using chemically synthesized peptide fragments of a viral protein subunit. This method has several advantages over the other methods of producing vaccines, including purity of the product, reproducibility and specificity of the immune response.
Surface antigens of an infecting virus can elicit T cell and B cell responses. From the work of Milich and coworkers (Milich et al., J. Exp. Med. 164:532, 1986; Milich and McLachlan, Science, 232:1398, 1986) it is clear that some regions of a protein's peptide chain can possess either T cell or B cell epitopes. These epitopes are frequently distinct from each other and can comprise different peptide sequences. Other examples include the work of Maizel et al., (Eur. J. Immunol. 10:509, 1980) for hen egg-white lysozyme, and Senyk et al., (J. Exp. Med., 133:1294, 1971) for glucagon. Thus, short stretches of a protein sequence can elicit a T cell response but not a B cell response. A more complete review of these and other observations pertinent to this point is included in the work of Livingstone and Fathman (Ann. Rev. Immunol., 5:477, 1987).
A short peptide region within the surface protein of infectious Hepatitis B virus has been shown to elicit only a T cell response in mice (Milich et al., 1986). Specifically, a synthetic peptide, whose sequence is derived from amino acids numbered 120-132 located within the pre-S(2) domain of the Hepatitis B surface antigen gene, elicited a very strong T cell priming response to the peptide but stimulated only a very weak antibody response. In other words, mice mounted a poor antibody response to that peptide, but the T cells of immunized mice were efficiently primed (i.e. activated) to recognize that peptide as measured in T cell proliferation assays (Milich et al., 1986). The low level of the antibody produced by mice immunized with this peptide did not bind to the native viral surface antigen. The sequence of this T cell active peptide is:
Amino terminal-MQWNSTTFHQTLQ-carboxy-terminal. The single letter code for amino acids used throughout this application is: A, alanine; C cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; and Y, tyrosine.
In contrast to the above-described results, a second peptide sequence (amino acids 132-145) elicited a very weak T-cell response in mice (Milich et al., 1986). This second peptide did, however, efficiently bind antibody raised against it under conditions where a T cell epitope is provided.
The sequence of the second or B cell active peptide is:
Amino terminal-DPRVRGLYFPAGG-carboxy-terminal. Mice were also immunized with a longer peptide made up of both of the above-mentioned T- and B-active peptide sequences. In this case, high titers of antibody were produced against the B site peptide but not the T site peptide. The combination of both T- and B-sites within one peptide should stimulate both T and B cell responses, as measured by producing a specific antibody to the B cell epitope of the peptide chain. Synthetic peptide antigens may be constructed to produce two types of immune responses: T-cell only and T cell combined with a B cell response.
Cellular immune responses provide a major mechanism for reducing the growth of virus-infected cells (Doherty et al., Adv. Cancer Res., 42:1, 1985). A report by Earl et al., (Science, 234:728, 1986) demonstrated T-lymphocyte priming and protection against the Friend virus (a retrovirus)-induced mouse leukemia by a viral surface protein vaccine. Direct evidence for the role of a subset of T-lymphocytes (OKT8/LEU2 positive) in suppressing HIV growth in vitro was recently obtained by Walker et al., (Science, 234:1563, 1986). This study further demonstrated that, after depletion of CD8
+
T-lymphocytes from the blood of HIV-infected individuals, large quantities of HIV were isolated from peripheral blood mononuclear cells of four of seven asymptomatic, seropositive homosexual men who were initially virus-negative or had very low levels of virus. Thus, the CD8
+
subset of T-lymphocytes may play a role in virus infected individuals to prevent HIV replication and disease progression.
SUMMARY OF THE INVENTION
The present invention contemplates a peptide, a peptide multimer, an aqueous composition containing the peptide multimer and a method of using the composition.
A peptide of the invention contains 7 to about 30 amino acid residues, and has a sequence that corresponds to a conserved domain of an HIV protein such as the gp160 envelope and core proteins. Preferred peptides have a sequence that corresponds to a portion of a conserved domai

Affiliated with

Also associated with

Rating

Prophylaxis and therapy of acquired immunodeficiency syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prophylaxis and therapy of acquired immunodeficiency syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prophylaxis and therapy of acquired immunodeficiency syndrome will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2526061